NEW HAVEN, Conn., May 25, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies for people with debilitating diseases, including ultra-rare disorders, will provide an overview of its platforms and pipeline at an in-person Research and Development (R&D) Day taking place on May 31 in New Haven, CT, concurrently with the Yale Ventures Innovation Summit 2023. Members of Biohaven's senior management team and key opinion leaders will be meeting with investors and research analysts. Topics for discussion include:
Read more at prnewswire.comhello world
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
